Actual or ideal body weight to calculate CD34+ cell dose in patients undergoing autologous hematopoietic SCT for myeloma?

Bone Marrow Transplantation

Volumn 43, Issue 4, 2009, Pages 301-305

  Singh, V ^a   Krishnamurthy, J ^a   Duffey, S ^a   Meagher, R ^a   Villa, M ^a   Monreal, J ^a   Evens, A ^a   Frankfurt, O ^a   Altman, J ^a   Gordon, L ^a   Tallman, M ^a   Williams, S ^a   Winter, J ^a   Singhal, S ^a   Mehta, J ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; MELPHALAN;

ACTUAL BODY WEIGHT; ADULT; AGED; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BODY WEIGHT; CELL COUNT; CONTROLLED STUDY; DOSE CALCULATION; DRUG MEGADOSE; ENGRAFTMENT; FEMALE; HUMAN; IDEAL BODY WEIGHT; MAJOR CLINICAL STUDY; MALE; MYELOMA; NEUTROPHIL COUNT; OUTCOME ASSESSMENT; PRIORITY JOURNAL; THROMBOCYTE COUNT;

ADULT; AGED; ANTIGENS, CD34; BIOLOGICAL MARKERS; BODY MASS INDEX; BODY WEIGHT; COMBINED MODALITY THERAPY; FEMALE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MELPHALAN; MIDDLE AGED; MULTIPLE MYELOMA; RETROSPECTIVE STUDIES; TRANSPLANTATION, AUTOLOGOUS;

EID: 61449258351     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2008.322     Document Type: Article

References (14)

1. Waples JM, Moreb JS, Sugrue M, Belanger G, Kubilis P, Lynch JW et al Comparison of autologous peripheral blood stem cell dosing by ideal vs actual body weight. Bone Marrow Transplant 1999; 23: 867-873.
2. Singhal S, Powles R, Sirohi B, Kulkarni S, Treleaven J, Mehta J. CD34+ cell dose based upon ideal body weight (IBW) is a better predictor of transplant-related mortality (TRM) and disease-free survival (DFS) than that based upon actual body weight (ABW). Blood 2002; 100: 1667.
3. Ali MY, Oyama Y, Monreal J, Winter JN, Tallman MS, Williams SF et al Ideal or actual body weight to calculate CD34+ cell doses for autologous hematopoietic stem cell transplantation? Bone Marrow Transplant 2003; 31: 861-864.
4. Cilley J, Rihn C, Monreal J, Gordon LI, Singhal S, Tallman MS et al Ideal or actual body weight to calculate CD34+ cell doses for allogeneic hematopoietic stem cell transplantation? Bone Marrow Transplant 2004; 33: 161-164.
5. Singhal S, Gordon LI, Tallman MS, Winter JN, Evens AO, Frankfurt O et al. Ideal rather than actual body weight should be used to calculate cell dose in allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2006; 37: 553-557 erratum in: Bone Marrow Transplant 2006; 37: 1067).
6. Maclean PS, Parker AN, McQuaker IG, Clark AD, Farrell E, Douglas KW. Body weight correlates better with engraftment after PBSC autograft than actual body weight, but is under-estimated in myeloma patients possibly due to disease-related height loss. Bone Marrow Transplant 2007; 40: 665-669.
7. Topcuoglu P, Akcaglayan Soydan E, Ekiz F, Ayyildiz E, Dalva K, Ozcan M et al. To calculate the quantity of CD34+ cells infused? A single center cohort study based on actual, ideal or adjusted ideal body weight. Transfus Apher Sci 2007; 36: 275-280.
8. Mehta J, Singhal S. High-dose chemotherapy and autologous hematopoietic stem cell transplantation in myeloma patients under the age of 65 years. Bone Marrow Transplant 2007; 40: 1101-1114.
9. Gidron A, Verma A, Doyle M, Boggio L, Evens A, Gordon L et al. Can the stem cell mobilization technique influence CD34+ cell collection efficiency of leukapheresis procedures in patients with hematologic malignancies? Bone Marrow Transplant 2005; 35: 243-246.
10. Egan K, Singh V, Gidron A, Mehta J. Correlation between serum lactate dehydrogenase and stem cell mobilization. Bone Marrow Transplant 2007; 40: 931-934.
11. Devine DJ. Gentamicin therapy. Drug Intell Clin Pharm 1974; 8 650-655.
12. Sutherland DR, Anderson L, Keeney M, Nayar R, Chin-Yee I. The ISHAGE guidelines for CD34+ cell determination by flow cytometry. International Society of Hematotherapy and Graft Engineering. J Hematother 1996; 5: 213-226.
13. Verma A, Pedicano J, Trifilio S, Singhal S, Tallman M, Winter J et al How long after neutrophil recovery should myeloid growth factors be continued in autologous hematopoietic stem cell transplant recipients? Bone Marrow Transplant 2004; 33: 715-719.
14. 9/1 neutrophils on 3 consecutive days to define myeloid recovery. Bone Marrow Transplant 2002; 30: 749-752.